A detailed history of Voya Investment Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 17,941 shares of RCUS stock, worth $282,929. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,941
Previous 18,340 2.18%
Holding current value
$282,929
Previous $279,000 1.79%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$13.69 - $18.01 $5,462 - $7,185
-399 Reduced 2.18%
17,941 $274,000
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $5,427 - $6,874
372 Added 2.07%
18,340 $279,000
Q1 2024

May 15, 2024

SELL
$14.83 - $20.18 $202,473 - $275,517
-13,653 Reduced 43.18%
17,968 $339,000
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $3,250 - $4,750
242 Added 0.77%
31,621 $603,000
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $4,722 - $6,308
268 Added 0.86%
31,379 $563,000
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $18,310 - $23,770
1,079 Added 3.59%
31,111 $631,000
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $15,209 - $22,061
953 Added 3.28%
30,032 $547,000
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $42,749 - $77,490
2,170 Added 8.06%
29,079 $601,000
Q3 2022

Mar 03, 2023

SELL
$23.23 - $30.07 $50,409 - $65,251
-2,170 Reduced 7.46%
26,909 $703,000
Q3 2022

Nov 14, 2022

BUY
$23.23 - $30.07 $49,967 - $64,680
2,151 Added 8.69%
26,909 $704,000
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $121,988 - $267,128
7,080 Added 40.05%
24,758 $627,000
Q4 2021

Feb 14, 2022

SELL
$31.38 - $48.47 $10,418 - $16,092
-332 Reduced 1.84%
17,678 $715,000
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $10,920 - $17,169
-480 Reduced 2.6%
18,010 $494,000
Q1 2021

May 17, 2021

BUY
$26.16 - $41.39 $1,595 - $2,524
61 Added 0.33%
18,490 $519,000
Q4 2020

Feb 16, 2021

BUY
$17.0 - $32.36 $72,471 - $137,950
4,263 Added 30.09%
18,429 $478,000
Q3 2020

Nov 16, 2020

BUY
$17.14 - $25.47 $46,449 - $69,023
2,710 Added 23.66%
14,166 $243,000
Q2 2020

Aug 14, 2020

SELL
$13.97 - $36.56 $75,046 - $196,400
-5,372 Reduced 31.92%
11,456 $283,000
Q4 2019

Feb 14, 2020

BUY
$7.33 - $10.79 $14,315 - $21,072
1,953 Added 13.13%
16,828 $170,000
Q2 2019

Aug 14, 2019

BUY
$7.29 - $13.38 $14,018 - $25,729
1,923 Added 14.85%
14,875 $118,000
Q4 2018

Feb 14, 2019

BUY
$9.74 - $14.5 $126,152 - $187,804
12,952 New
12,952 $139,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.